Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 4/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.43 |
| ▸ | TLK2 | Q86UE8 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5361191 | 0.81 | RET (0.46) | RETLRRK2TLK2MEN1KMT2A | |
| SCHEMBL5370007 | 0.81 | RET (0.42) | RETLRRK2TLK2MEN1KMT2A | |
| SCHEMBL5358278 | 0.80 | MEN1 (0.46) | RETLRRK2TLK2MEN1KMT2A | |
| SCHEMBL5358237 | 0.80 | LRRK2 (0.44) | RETLRRK2TLK2MDM2KDR | |
| SCHEMBL5368750 | 0.80 | RET (0.71) | RETTLK2MEN1KMT2AKDR | |
| SCHEMBL5362148 | 0.78 | KDR (0.48) | RETTLK2KDRPDPK1PDGFRB | |
| SCHEMBL5366782 | 0.78 | PDPK1 (0.60) | TLK2MEN1KMT2AKDRPDPK1 | |
| SCHEMBL6297819 | 0.76 | LRRK2 (0.60) | RETLRRK2MDM2PDGFRB | |
| SCHEMBL6297823 | 0.76 | LRRK2 (0.60) | RETLRRK2MDM2PDGFRB | |
| SCHEMBL5364110 | 0.76 | PDPK1 (0.56) | RETLRRK2MEN1KMT2AKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
| EP-1247803-A2 | Indolinone compounds suitable for modulation of protein kinases | Sugen, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | RET 283/4885LRRK2 289/4885TLK2 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.